ARFGAP2 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-mediated polyclonal knockout cell population targeting the human ARFGAP2 gene in the HT29 colorectal adenocarcinoma cell line. This model enables functional investigation of ARFGAP2 loss in a disease-relevant epithelial context without selection for clonal populations, maintaining polyclonal heterogeneity. The knockout disrupts ARFGAP2 expression, providing a tool to dissect its roles in Golgi homeostasis and vesicular trafficking.
The HT29 cell line, derived from a colorectal adenocarcinoma of a 44-year-old female patient, exhibits epithelial morphology and adherent growth. Widely employed as a model for colorectal cancer, it recapitulates aspects of intestinal epithelial biology, including barrier formation, drug transport, and metabolism. Its genetic background and well-characterized secretory pathway make it suitable for studying protein trafficking perturbations.
ARFGAP2 functions as a GTPase-activating protein for ARF1, accelerating GTP hydrolysis on Golgi-localized ARF1 to trigger COPI coat disassembly. This activity is essential for retrograde transport from the Golgi to the endoplasmic reticulum, facilitating cargo retrieval and maintaining organelle organization. ARFGAP2 is recruited to Golgi membranes by ARF1-GTP and regulated by protein kinase D signaling. Its catalytic action promotes the conversion of ARF1-GTP to ARF1-GDP, leading to coatomer dissociation and enabling fusion of retrograde vesicles with the ER. Interacting partners include the coatomer complex, KDEL receptor, p24 family proteins, and ERGIC-53, which together mediate selective cargo trafficking. Key pathway components include ARF1, COPI coatomer subunits (??, ??, ??’, ??, ??, ??, ??), SNARE proteins, and Golgi matrix elements.
In HT29 colorectal adenocarcinoma cells, ARFGAP2 loss disrupts Golgi-to-ER retrieval, likely impairing the processing and secretion of glycoproteins and altering ER homeostasis. This perturbation can activate the unfolded protein response and affect cellular functions such as migration and invasion, which are critical in cancer progression. Consequently, this knockout model provides a physiologically relevant system to explore Golgi dysfunction in colorectal cancer and its impact on tumor cell behavior.
Researchers can employ these polyclonal knockout cells in a variety of assays to investigate Golgi morphology via immunofluorescence staining of markers like GM130 and giantin, assess COPI complex integrity by western blotting for ??-COP, and monitor ER stress through RT-qPCR analysis of CHOP and BiP expression. Functional studies may include migration and invasion assays, MTT viability tests, and drug sensitivity profiling to evaluate the consequences of defective retrograde transport on cancer cell adaptation. These cells are also suitable for screening small molecules that modulate Golgi function or restore protein trafficking. For further technical details and customized applications, please contact Ascent Research.
